 | • レポートコード：MRC2304D138 • 出版社/出版日：Transparency Market Research / 2023年1月17日 • レポート形態：英文、PDF、240ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、カテーテル関連血流感染症の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療種類別（抗菌剤、抗生物質ロック療法）分析、感染源別（コアグラーゼ陰性ブドウ球菌、黄色ブドウ球菌、腸内グラム陰性菌、イースト菌、その他）分析、流通チャネル別（病院内薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、AstraZeneca、CorMedix, Inc.、Citus Pharmaceuticals、Fresenius Medical Care、Glenmark Pharmaceuticals Ltd.、Geistlich Pharma、Merck & Co., Inc.、Pfizer、TauroPhar GmbH、Xellia Pharmaceuticals Ltd.などの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のカテーテル関連血流感染症市場規模：治療種類別 - 抗菌剤治療の市場規模 - 抗生物質ロック療法の市場規模 ・世界のカテーテル関連血流感染症市場規模：感染源別 - コアグラーゼ陰性ブドウ球菌感染の市場規模 - 黄色ブドウ球菌感染の市場規模 - 腸内グラム陰性菌感染の市場規模 - イースト菌感染の市場規模 - その他感染源の市場規模 ・世界のカテーテル関連血流感染症市場規模：流通チャネル別 - 病院内薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のカテーテル関連血流感染症市場規模：地域別 - 北米のカテーテル関連血流感染症市場規模 - ヨーロッパのカテーテル関連血流感染症市場規模 - アジア太平洋のカテーテル関連血流感染症市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Catheter-related Bloodstream Infections Market – Scope of Report
TMR’s report on the global catheter-related bloodstream infections market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global catheter-related bloodstream infections market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global catheter-related bloodstream infections market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the catheter-related bloodstream infections market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global catheter-related bloodstream infections market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global catheter-related bloodstream infections market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global catheter-related bloodstream infections market.
The report delves into the competitive landscape of the global catheter-related bloodstream infections market. Key players operating in the global catheter-related bloodstream infections market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global catheter-related bloodstream infections market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market catheter-related bloodstream infections.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Catheter-related Bloodstream Infections Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Anti-microbial Agents
6.3.2. Antibiotic Lock Therapy
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Source of Infection
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Source of Infection, 2017–2031
7.3.1. Coagulase-negative Staphylococcus
7.3.2. S. aureus
7.3.3. Enteric Gram-negative Bacilli
7.3.4. Yeasts
7.3.5. Enterococci & Streptococci
7.3.6. Pseudomonas
7.3.7. Others
7.4. Market Attractiveness Analysis, by Source of Infection
8. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Catheter-related Bloodstream Infections Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Catheter-related Bloodstream Infections Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Anti-microbial Agents
10.2.2. Antibiotic Lock Therapy
10.3. Market Value Forecast, by Source of Infection, 2017–2031
10.3.1. Coagulase-negative Staphylococcus
10.3.2. S. aureus
10.3.3. Enteric Gram-negative Bacilli
10.3.4. Yeasts
10.3.5. Enterococci & Streptococci
10.3.6. Pseudomonas
10.3.7. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Source of Infection
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Catheter-related Bloodstream Infections Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Anti-microbial Agents
11.2.2. Antibiotic Lock Therapy
11.3. Market Value Forecast, by Source of Infection, 2017–2031
11.3.1. Coagulase-negative Staphylococcus
11.3.2. S. aureus
11.3.3. Enteric Gram-negative Bacilli
11.3.4. Yeasts
11.3.5. Enterococci & Streptococci
11.3.6. Pseudomonas
11.3.7. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Source of Infection
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Catheter-related Bloodstream Infections Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Anti-microbial Agents
12.2.2. Antibiotic Lock Therapy
12.3. Market Value Forecast, by Source of Infection, 2017–2031
12.3.1. Coagulase-negative Staphylococcus
12.3.2. S. aureus
12.3.3. Enteric Gram-negative Bacilli
12.3.4. Yeasts
12.3.5. Enterococci & Streptococci
12.3.6. Pseudomonas
12.3.7. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Source of Infection
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Catheter-related Bloodstream Infections Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Anti-microbial Agents
13.2.2. Antibiotic Lock Therapy
13.3. Market Value Forecast, by Source of Infection, 2017–2031
13.3.1. Coagulase-negative Staphylococcus
13.3.2. S. aureus
13.3.3. Enteric Gram-negative Bacilli
13.3.4. Yeasts
13.3.5. Enterococci & Streptococci
13.3.6. Pseudomonas
13.3.7. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Source of Infection
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Catheter-related Bloodstream Infections Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Anti-microbial Agents
14.2.2. Antibiotic Lock Therapy
14.3. Market Value Forecast, by Source of Infection, 2017–2031
14.3.1. Coagulase-negative Staphylococcus
14.3.2. S. aureus
14.3.3. Enteric Gram-negative Bacilli
14.3.4. Yeasts
14.3.5. Enterococci & Streptococci
14.3.6. Pseudomonas
14.3.7. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Source of Infection
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. AstraZeneca
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. CorMedix, Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Citus Pharmaceuticals
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Fresenius Medical Care
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Glenmark Pharmaceuticals Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Geistlich Pharma
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Merck & Co., Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Pfizer
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. TauroPhar GmbH
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Xellia Pharmaceuticals Ltd.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview